title: [Effects of cyclophosphamide on the length of remission in patients suffering from glomerulonephritis with nephrotic syndrome].
abstract: The authors performed retrospective evaluation of recurrence rate and the length of nephrotic syndrome (NS) remission in 21 patients with chronic glomerulonephritis (GN), who suffered from a first NS attack, cured by corticosteroid (CS) monotherapy; 16 patients had mesangioproliferative GN, 1--mesangiocapillary GN, 1--membranous GN, 3 patients did not undergo biopsy. After obtaining steroid remission of NS, 11 patients (Group I) continued receiving CS in maintaining doses during the next 6 7 +/- 1.0 months; the other 10 patients (Group II) received maintaining doses of CS during the next 5.5 +/- 0.5 months plus cyclophosphamide (CFA) daily or as pulse therapy during 19.7 +/- 3.5 months. There was almost a double increase of mean remission length in Group II vs. Group I (47.6 +/- 9.8 and 25.3 +/- 6.4 months, respectively). There was only one case of a NS relapse in Group II vs. 7 in Group I, which means that the risk of a NS relapse was 7.7 times higher in patients receiving only CS vs. patients on combination of CS and CFA, p = 0. 004. The results of this small retrospective study suggest that administration of CFA as supporting therapy after obtaining steroid remission of NS allows its substantial prolongation in patients with chronic GN.
authors.forename: V L
authors.initials: VL
authors.lastname: Duman
authors.forename: L I
authors.initials: LI
authors.lastname: Shkerina
authors.forename: E M
authors.initials: EM
authors.lastname: Shilov
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D003627:Data Interpretation, Statistical; D004359:Drug Therapy, Combination; D005260:Female; D005921:Glomerulonephritis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D015432:Glomerulonephritis, Membranoproliferative / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D015433:Glomerulonephritis, Membranous / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide